Pola Pharma Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
10
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Antimycotic pharmaceutical composition (US 9,050,271) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Jan 21, 2027The maintenance fee for Method of evaluating pharmaceutical preparation containing luliconazole and index substance (US 9,085,554) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation (US 9,145,401) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal (US 9,199,977) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,268,876 | Pharmaceutical composition for external use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,349,882 | Pharmaceutical composition for external use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,039,452 | Antifungal medicinal compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,202,898 | Pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record | |
| US 8,030,338 | Method for producing 2-nitroimidazole derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 8,513,296 | Pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record | |
| US 9,968,591 | Antifungal composition In force · From the USPTO record | In force | From the USPTO record | |
| US 9,480,678 | Antifungal pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record | |
| US 10,130,610 | Antimycotic pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record | |
| US 8,952,044 | Antimycotic pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 22: 2 patents in force now held by others · 10 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 no status recorded